Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XPO1 inhibitor plus PD-1 antibody in relapsed/refractory primary CNS lymphoma
ChiCTR2300074353Phase 2Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PD-1 Monoclonal Antibody in primary central nervous system lymphoma (PCNSL), sponsored by Huashan Hospital. Primary endpoints: progression-free survival and overall response rate. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
PD-1 Monoclonal Antibody
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on ChiCTR2300074353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074353.